L 698544

Drug Profile

L 698544

Alternative Names: CNDQ

Latest Information Update: 07 Jan 2000

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antiepileptic drugs; Neuroprotectants
  • Mechanism of Action AMPA receptor antagonists; Glycine NMDA-associated antagonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Epilepsy

Most Recent Events

  • 07 Jan 2000 Discontinued-Preclinical for Epilepsy in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top